Status:
NOT_YET_RECRUITING
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Lead Sponsor:
Children's Blood and Cancer Center at Dell Children's Medical Center
Conditions:
Sickle Cell Disease
Sickle Cell Crisis
Eligibility:
All Genders
1-21 years
Phase:
PHASE4
Brief Summary
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV...
Detailed Description
Sickle Cell Disease is characterized by a point mutation that causes red cell polymerization and clinically results in pain events, called vaso-occlusive crises (VOC), and end organ damage. VOC is the...
Eligibility Criteria
Inclusion
- Pediatric patients with sickle cell disease (any genotype) who present to DCMC Emergency department or outpatient hematology clinic with acute pain.
Exclusion
- Patients receiving NSAID medication \<6 hours from presentation
- known kidney injury
- sickle nephropathy
- bleeding concerns
- allergy to NSAID medication
- chronic pain patient
- hemodynamic instability as defined by the treating provider
Key Trial Info
Start Date :
September 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 15 2028
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT06579703
Start Date
September 30 2024
End Date
February 15 2028
Last Update
August 30 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.